Genmab to fund drug development $182m ABB
Genmab, a Danish biotech firm, raised Dkr998m ($182m) through a primary ABB on Thursday night, which will help fund the development of new drugs by the company.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts